Neural Tube Defects (including Spina Bifida) — Clinical Documentation Guide (2026)

🔍 1. Definition

Neural tube defects (NTDs) are a group of serious congenital malformations resulting from incomplete closure of the neural tube during embryonic development, typically between the 17th and 30th day after conception — often before a woman knows she is pregnant. The neural tube is the embryonic precursor to the brain and spinal cord. Failure to close at the cephalic (head) end produces defects such as anencephaly and encephalocele; failure to close caudally produces spina bifida and related spinal anomalies. According to the CDC, NTDs affect approximately 1 in 1,000 pregnancies in the United States each year, making them among the most common serious birth defects.

Spina bifida is the most prevalent NTD among live-born infants. It occurs when the vertebral arches fail to fuse, leaving the spinal cord and/or meninges exposed or herniated. Per CDC spina bifida surveillance data, approximately 1,278 babies are born with spina bifida each year in the US (roughly 1 in every 2,875 births). Spina bifida exists on a spectrum from the occult (hidden) form — spina bifida occulta — to severe open (cystica) forms including meningocele and myelomeningocele.

Anencephaly (ICD-10-CM Q00.0) occurs when most of the brain, skull, and scalp fail to form; it is uniformly lethal. Encephalocele (Q01.x) involves herniation of brain tissue and/or meninges through a skull defect. Microcephaly (Q02) denotes abnormally small head circumference, which may be associated with NTDs or intrauterine infection. Additional related anomalies include Arnold-Chiari malformation (Q07.0x), tethered spinal cord (Q06.8), and syringomyelia (G95.0).

Folate deficiency in early pregnancy is the primary modifiable risk factor. Since mandatory folic acid fortification of enriched grain products began in the US in 1998, the prevalence of spina bifida has declined substantially, though recent CDC surveillance (2026) confirms the current prevalence remains about 4 per 10,000 live births.

🗂️ 2. Alternative Terminology

Accurate code selection requires recognizing the multiple clinical terms used across providers, surgical reports, and radiology documentation for NTDs and related conditions.

🩺 3. Signs & Symptoms

Clinical manifestations of NTDs depend heavily on the type of defect and, for spina bifida, the anatomic level of the lesion. Lesion level is one of the most important prognostic and coding-relevant variables. Higher (cervicothoracic) lesions carry significantly greater morbidity and mortality than lower (lumbosacral) lesions, as confirmed by CDC spina bifida survival research (2026).

Spina bifida (myelomeningocele) — by lesion level:

• Cervical (C1–C8): Upper limb weakness/paralysis, respiratory compromise, ventilator dependence possible; high association with Chiari II malformation and hydrocephalus
• Thoracic (T1–T12): Paraplegia, absent trunk control, loss of sensation below lesion; severe scoliosis common; bowel/bladder dysfunction
• Lumbar (L1–L5): Most common level for myelomeningocele; hip flexion possible, leg function variable; characteristic foot deformities (clubfoot, equinovarus); neurogenic bladder/bowel universal
• Sacral (S1–S5): Near-normal ambulation; primary presenting features may be bowel/bladder dysfunction and perianal sensory loss

Hydrocephalus occurs in approximately 80–90% of patients with lumbar myelomeningocele and is the primary intracranial comorbidity. In fetal surgery cases (MOMS trial), prenatal repair reduced shunt requirements from ~82% to ~40% at 12 months per Children’s Minnesota MOMS trial data.

Arnold-Chiari malformation type II is present in virtually all myelomeningocele patients; symptoms include posterior fossa crowding, brainstem compression, stridor, apnea, and feeding difficulties in infants.

Spina bifida occulta (Q76.0) is often asymptomatic but may present in childhood or adulthood with back pain, foot deformity, tethered cord symptoms (lower extremity weakness, bladder dysfunction, gait changes).

Additional common manifestations across NTD spectrum:

• Neurogenic bladder (N31.x) — overactive, underactive, or mixed; urinary tract infections common
• Neurogenic bowel (K59.2) — constipation, incontinence, bowel management programs
• Lower extremity paralysis or weakness (G82.2x for paraplegia/paraparesis)
• Orthopedic complications: scoliosis, hip dysplasia, clubfoot, pathologic fractures
• Skin complications: decubitus ulcers due to sensory loss
• Latex allergy (high prevalence in spina bifida population — document as allergy)
• Tethered cord: progressive neurologic deterioration, scoliosis, bladder changes
• Syringomyelia (G95.0): dissociated sensory loss, cape-like pain distribution, progressive weakness
• Anencephaly: incompatibility with prolonged life; stillbirth or neonatal death

🧭 4. Differential Diagnosis

Distinguishing NTD subtypes and related spinal/cranial anomalies is critical for accurate code assignment and appropriate clinical management. The following differential diagnoses are relevant for both prenatal detection and postnatal care.

📋 5. Clinical Indicators for Coders/CDI

The following clinical indicators should prompt coders and CDI specialists to review documentation, assign additional codes, or initiate physician queries when treating patients with neural tube defects.

🦴 6. Anatomy & Pathophysiology

The neural tube forms from the neural plate — a specialized region of ectoderm — which folds inward and fuses along the dorsal midline. Fusion proceeds bidirectionally from the cervical region, completing at the rostral (cranial) neuropore by day 24 and the caudal neuropore by day 26–28. Failure of closure at any point along this tract results in an NTD at the corresponding level.

Multifactorial etiology of NTDs involves:

• Folate-related pathways: Folic acid is essential for DNA methylation and rapid cell division during neural tube closure. The CDC attributes mandatory grain fortification (400 mcg folic acid/day) since 1998 with reducing NTD prevalence by 28–36% in the US.
• Genetic factors: Mutations in genes regulating folate metabolism (MTHFR C677T polymorphism), planar cell polarity (VANGL1/2, CELSR1), and neural tube closure pathways contribute to NTD risk.
• Environmental/teratogenic exposures: Valproic acid (anti-epileptic), carbamazepine, maternal diabetes (pre-gestational), hyperthermia, and obesity increase risk.
• Hispanic ethnicity: Has the highest US rate of spina bifida per CDC demographic data.

Open spina bifida (myelomeningocele) pathophysiology: The exposed spinal cord suffers dual injury — the primary developmental defect (malformation) and secondary injury from amniotic fluid chemical irritation and mechanical trauma throughout gestation (the “two-hit” hypothesis). Fetal surgery aims to halt secondary injury and has been validated by the MOMS trial. The lesion disrupts motor, sensory, and autonomic neural pathways below the level of the defect, producing the characteristic neurologic pattern: motor paralysis and sensory loss in dermatomes below the lesion, neurogenic bladder (due to disrupted sacral micturition center input), and neurogenic bowel (due to disrupted colorectal motility and sphincter control).

Hydrocephalus in spina bifida results from the associated Arnold-Chiari type II malformation: downward displacement of the brainstem and cerebellum through the foramen magnum obstructs CSF flow, leading to progressive ventricular dilation. Left untreated, this causes brain injury, developmental delay, and death.

Syringomyelia (G95.0) often develops as a secondary complication of Chiari malformation or tethered cord. CSF turbulence caused by tonsillar herniation creates a pressure differential that drives fluid into the central spinal cord canal, creating a progressive fluid-filled cavity (syrinx) that causes dissociated sensory loss and progressive motor dysfunction.

Tethered cord occurs when the conus medullaris is anchored below the normal L1–L2 level by a tight filum terminale, lipoma, scar tissue, or other structure. Progressive traction on the cord during growth causes ischemic injury, manifesting as worsening leg weakness, spasticity, back pain, and bladder deterioration.

💊 7. Medication Impact / Treatment

Pharmacologic management of NTDs focuses primarily on prevention (folic acid supplementation), management of associated complications, and supportive care. There is no curative medication for the structural defect itself.

Prevention — Folic Acid:

• The CDC and American Academy of Pediatrics (AAP) recommend 400 mcg of folic acid daily for all women of reproductive age and 4 mg/day for those with a prior NTD-affected pregnancy (high-risk dosing).
• Document folate deficiency as E53.8 when present; use Z13.88 for nutritional disorder screening.
• Anti-seizure medications that are folate antagonists (valproic acid, carbamazepine) require additional supplementation and counseling; document medication-related risk when applicable.

Urologic medications (neurogenic bladder):

• Anticholinergics (oxybutynin, solifenacin) — reduce detrusor overactivity; reduce UTI risk
• Mirabegron (beta-3 agonist) — for overactive neurogenic bladder
• Alpha-blockers (tamsulosin) — facilitate bladder outlet relaxation
• Botulinum toxin A (onabotulinumtoxinA) — intravesical injection for refractory neurogenic overactivity
• Clean intermittent catheterization (CIC) — the primary bladder management strategy, not a medication but critical to document

Bowel management:

• Polyethylene glycol (PEG), docusate sodium, senna — bowel program medications
• Transanal irrigation systems may be used in older patients

Pain management / spasticity:

• Baclofen (oral or intrathecal pump) — spasticity management; intrathecal baclofen pump requires CPT 62350–62362
• NSAIDs and gabapentin/pregabalin — neuropathic pain management in tethered cord or syringomyelia

Shunt infection prophylaxis: Perioperative antibiotic prophylaxis for shunt procedures; document causative organism when infection occurs (T85.738x — infection of CSF shunt).

CDI note: Document all chronic medications and their indications in NTD patients; medication lists often reveal undocumented comorbidities (e.g., oxybutynin use implies neurogenic bladder; clean intermittent catheterization implies neurogenic bladder/urinary retention).

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 8. ICD-10-CM Guidelines (FY2026)

The following guidelines govern coding of neural tube defects under FY2026 ICD-10-CM Official Guidelines for Coding and Reporting (CMS/NCHS). These are congenital anomalies coded from Chapter 17 (Q00–Q99), with important sequencing and combination code rules.

8.1 Congenital Anomalies vs. Acquired Conditions

Spina bifida and other NTDs are classified as congenital malformations under ICD-10-CM Chapter 17 (Q00–Q99). Per the Official Guidelines (Section I.C.17): when a congenital malformation is the principal reason for the encounter, sequence the Q-code first. When the patient is admitted for a complication of the congenital anomaly (e.g., shunt revision, UTI from neurogenic bladder), the complication is sequenced as the principal diagnosis and the underlying congenital anomaly is coded as an additional code.

8.2 Spina Bifida Code Selection (Q05.x)

Code category Q05 (Spina bifida) requires specificity in two dimensions:

1. Level of lesion: Cervical (Q05.0/Q05.5), Thoracic (Q05.1/Q05.6), Lumbar (Q05.2/Q05.7), Sacral (Q05.3/Q05.8), Unspecified (Q05.4/Q05.9)
2. Presence or absence of hydrocephalus: Q05.0–Q05.4 include hydrocephalus; Q05.5–Q05.9 do not

When hydrocephalus is present and coded within Q05.0–Q05.4, do not additionally assign Q03.x or G91.x for the same hydrocephalus — it is captured in the combination code. However, if the patient has a separate, distinct acquired hydrocephalus (e.g., post-hemorrhagic, G91.1), that may be coded additionally.

8.3 Arnold-Chiari Malformation — Excludes1 note

Per the ICD-10-CM tabular for Q05: Arnold-Chiari syndrome type II (Q07.0x) is listed as an Excludes1 note under Q05. This means when a patient has spina bifida AND Arnold-Chiari type II, code Q07.01 (Arnold-Chiari with spina bifida) or Q07.03 (with spina bifida and hydrocephalus) may be used instead of Q05 for the Arnold-Chiari component, OR both may be reported if clinically warranted and documented separately. Clarify with physician documentation whether Chiari II is the principal reason for the encounter.

8.4 Spina Bifida Occulta (Q76.0)

Spina bifida occulta is classified under Q76 (Congenital malformations of spine and bony thorax), not under Q05. It is a radiologic finding of incomplete vertebral arch fusion with intact overlying skin. It does NOT carry the same clinical severity as open spina bifida and is not mapped to HCC v28. If tethered cord is also present and documented, additionally assign Q06.8.

8.5 Neurogenic Bladder Sequencing

Per ICD-10-CM tabular instructions for N31, there is a note to “Use additional code to identify any associated urinary incontinence (N39.3–N39.4-).” When neurogenic bladder is due to spinal cord lesion, G95.89 may also be applicable. The underlying NTD (Q05.x) should be the principal diagnosis when the encounter is for the congenital condition. Code N31.x as an additional code.

8.6 Prenatal Diagnosis Coding

When NTD is detected prenatally, the maternal record uses O35.0xx0–O35.0xx9 (Maternal care for (suspected) central nervous system malformation in fetus) or O35.8xx0 (other specified fetal abnormality). Abnormal AFP screening is coded O28.1 (abnormal biochemical finding on antenatal screening — note: O28.5 is abnormal chromosomal/genetic finding; AFP elevation on triple/quad screen is typically O28.1). The fetal condition itself is not coded in the maternal record unless it affects management.

8.7 Subsequent Encounters and Sequelae

For patients with spina bifida being managed long-term for sequelae (chronic neurogenic bladder, pressure ulcers from sensory loss, chronic paraplegia), the Q05.x code continues to be reported as an ongoing condition per the guidelines for congenital anomalies that persist throughout the patient’s life. These are not coded as “sequelae” (S-type codes); the original Q-code is used at every encounter where the condition is relevant to care.

🔢 9. ICD-10-CM Code Set (FY2026)

All codes verified against CMS FY2026 ICD-10-CM tabular and index, effective October 1, 2025.

🔎 10. Indexing

The following ICD-10-CM Alphabetic Index pathways are critical for accurate code location. Coders should follow the index route, then verify in the tabular.

🏥 11. CPT (2026)

The following CPT codes are relevant for surgical and procedural services related to neural tube defects. All codes verified against AMA CPT 2026.

🧾 12. HCPCS (2026)

HCPCS Level II codes are used for durable medical equipment (DME), prosthetics, orthotics, and supplies commonly required by NTD patients with functional impairments. All codes verified against CMS HCPCS 2026.

📚 13. AHA Coding Clinic (Recent Guidance)

The following AHA Coding Clinic for ICD-10-CM/PCS guidance is relevant to neural tube defect coding. Coders should verify current Coding Clinic availability through their AHA subscription.

💰 14. HCC / Risk Adjustment (v28)

The CMS-HCC Model Version 28, fully operative for Payment Year 2026, reorganized congenital and developmental condition categories. Accurate NTD coding directly impacts risk adjustment scores for Medicare Advantage plans and other risk-based contracts.

✍️ 15. CDI Query Templates

All queries below are designed to be non-leading and compliant with AHIMA and ACDIS physician query standards. Queries must present all clinically reasonable options and must not suggest a preferred response.

🧑‍⚕️ 16. Treatments (Clinical)

Treatment of neural tube defects is multidisciplinary and lifelong, involving neurosurgery, urology, orthopedics, physical/occupational therapy, and social work. The specific treatment plan depends on type and level of NTD, presence of associated anomalies (Chiari, hydrocephalus, tethered cord), and patient age.

Fetal Surgery (Prenatal)

The landmark Management of Myelomeningocele Study (MOMS trial), published in the New England Journal of Medicine (2011), established open prenatal MMC repair as superior to postnatal repair for selected patients. Per MOMS trial outcomes data:

• Prenatal repair reduced the rate of shunt placement at 12 months from 82% (postnatal) to 40%
• Improved motor outcomes at 30 months; 51% of prenatal repair patients walked community distances independently vs. 23% with postnatal repair
• Hindbrain herniation resolved in >90% on neonatal MRI after prenatal repair per CHOP MOMS outcomes
• Maternal and fetal risks include preterm labor, PPROM, uterine dehiscence; patients must meet strict inclusion criteria
• Fetoscopic approaches (minimally invasive fetal surgery) are being studied as alternatives to open hysterotomy
• CPT: 59897 (unlisted fetal invasive procedure) with appropriate documentation

Postnatal Surgical Management

• MMC closure (CPT 63704/63706): Within 24–48 hours of birth; primary goal is prevention of infection and preservation of neurologic function; does not restore lost function
• Hydrocephalus management: Ventriculoperitoneal (VP) shunt (CPT 62223) is most common; endoscopic third ventriculostomy (ETV, CPT 62201) in selected patients; shunt revision (CPT 62230) for malfunction or infection
• Chiari decompression: Posterior fossa decompression (CPT 61340/61343) for symptomatic Chiari II with brainstem compression
• Tethered cord release (CPT 63200): Laminectomy with surgical untethering; indicated when progressive neurologic deterioration, worsening scoliosis, or deteriorating bladder function attributed to tethering
• Syringomyelia management: Treat underlying cause (shunt, Chiari decompression, untethering); direct syrinx drainage rarely indicated
• Orthopedic surgery: Hip reconstruction, scoliosis correction (CPT 22800–22819), clubfoot repair (CTEV — CPT 28264/28268); timing individualized

Urologic Management

• Clean intermittent catheterization (CIC) — standard of care for neurogenic bladder management; typically initiated in infancy
• Vesicoureteral reflux surveillance — annual renal ultrasound and urodynamics recommended by the Spina Bifida Association Guidelines
• Bladder augmentation cystoplasty (CPT 51960) — for refractory high-pressure neurogenic bladder unresponsive to medical management
• Mitrofanoff procedure / continent catheterizable channel — for patients unable to perform standard urethral CIC

Rehabilitation and Long-Term Care

• Physical therapy — gait training, strengthening, mobility aid prescription
• Occupational therapy — adaptive equipment, school/vocational accommodations
• Pressure ulcer prevention — sensory loss requires dedicated skin care program; document pressure injury staging (L89.x) if present
• Neuropsychological evaluation — learning disabilities, attention deficits, and executive function challenges are common and should be documented
• Transition to adult care — multidisciplinary transition programs per Spina Bifida Association recommendations; survival into adulthood now expected for most patients

🎓 17. Patient Education / Summary

This section provides a clinical documentation summary for provider reference and patient-facing communication regarding neural tube defects.

Key Points for Patients and Families

• What is spina bifida? Spina bifida is a birth defect occurring when the spinal column does not close completely during the first month of pregnancy. It ranges from a mild form (spina bifida occulta, often with no symptoms) to a more severe form (myelomeningocele, open spina bifida) where the spinal cord and its covering protrude from the back.
• Can it be prevented? Taking folic acid (400 mcg daily) before and during early pregnancy significantly reduces the risk of NTDs. Women with a prior NTD pregnancy should take 4 mg daily and consult their physician. The CDC and AAP both recommend folic acid supplementation for all women of reproductive age.
• What is the outlook? With modern multidisciplinary care, most people with spina bifida live into adulthood. CDC surveillance data (2026) shows a 25-year survival probability of 82% for spina bifida patients. Quality of life and independence depend on the level of the spinal lesion and associated complications.
• Prenatal detection: Elevated maternal serum AFP (MSAFP) on second-trimester screening or characteristic findings on fetal ultrasound (banana sign, lemon sign, ventriculomegaly) can identify NTDs prenatally, allowing for planned delivery at a specialized center and consideration of fetal surgery.
• Fetal surgery option: For eligible pregnancies diagnosed with myelomeningocele, prenatal surgical repair before 26 weeks gestation has been shown to improve neurologic outcomes and reduce the need for brain shunts, based on the MOMS trial. This is only available at specialized fetal surgery centers.

Documentation Checklist for CDI Specialists

• ☐ Spina bifida type (myelomeningocele, meningocele, occulta) documented
• ☐ Level of spinal lesion (cervical, thoracic, lumbar, sacral) documented by surgeon or neurologist
• ☐ Hydrocephalus: present/absent/controlled by shunt documented
• ☐ Arnold-Chiari malformation: present/absent, type documented
• ☐ Neurogenic bladder: documented with type (overactive, flaccid, mixed)
• ☐ Neurogenic bowel: documented if applicable
• ☐ Paraplegia/paraparesis: documented with completeness and level if applicable
• ☐ Tethered cord: clinical diagnosis (not just imaging) documented if applicable
• ☐ Syringomyelia: clinically active vs. incidental imaging finding clarified
• ☐ Latex allergy documented in allergy list
• ☐ Shunt status documented (in situ, revised, infected) with reason
• ☐ Folate deficiency/supplementation documented if relevant to current encounter
• ☐ All active comorbidities impacting management coded (scoliosis, UTI, pressure injury, etc.)

Sources: CDC — Neural Tube Defects; CDC — About Spina Bifida; CDC — Spina Bifida Data and Statistics; Spina Bifida Association; AAPC ICD-10-CM Q05 — Spina Bifida; CMS FY2026 ICD-10-CM; AMA CPT 2026; AHA Coding Clinic; Kancherla et al. — Spina Bifida Mortality, CDC/Emory, 2026; Children’s Minnesota — MOMS Trial Outcomes.

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)